HMy2.CIR（人B淋巴母細(xì)胞瘤細(xì)胞）
CBP60725
詢 價(jià)
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | HMy2.CIR |
| Background: | The HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), by gamma irradiation and selection for loss of HLA class I antigen expression. |
| Morphology: | lymphoblast |
| Growth Mode: | suspension |
| Doubling Time: | N/A |
| DNA Profile: | Amelogenin: X CSF1PO: 6,10 D13S317: 11,13 D16S539: 9,13 D5S818: 10,13 D7S820: 7,12 THO1: 8 TPOX: 8 vWA: 1 Our Cell Line Authentication Service |
| Culture Medium: |
RPMI-1640+10%FBS HMy2.CIR完全培養(yǎng)基，# CBP60725M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Antigen Expression: | The CRL-1621cell line is reported to be positive for Epstein-Barr nuclear antigen (EBNA +) and Epstein-Barr viral capsid antigen (EBVCA +). |
| Genes Expressed: | The cells express no HLA A or B locus products, but do express small amounts of HLA Cw4. |
| Comments: | The cells are useful as host for transfected class I major histocompatibility antigen genes. Since the HMy2.CIR cell line was derived from the HMy.2 B lymphoblastoid cell line, a fast growing mutant of the ARH-77 cell line (ATCC CRL-1621), it is assumed to be EBNA positive. For more information, please contact us (4008-750-250). |
